Cargando…
suPAR and Team Nephrology
Primary focal segmental glomerulosclerosis (FSGS) accounts for nearly 10 % of patients who require renal replacement therapy. Elevated circulating levels of soluble urokinase receptor (suPAR) have been identified as a biomarker to discriminate primary FSGS from other glomerulopathies. Subsequent rep...
Autor principal: | Trachtman, Howard |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4026824/ https://www.ncbi.nlm.nih.gov/pubmed/24885021 http://dx.doi.org/10.1186/1741-7015-12-82 |
Ejemplares similares
-
suPAR: The Molecular Crystal Ball
por: Thunø, Maria, et al.
Publicado: (2009) -
suPAR: An Inflammatory Mediator for Kidneys
por: Sudhini, Yashwanth Reddy, et al.
Publicado: (2022) -
suPAR as a prognostic biomarker in sepsis
por: Donadello, Katia, et al.
Publicado: (2012) -
Reassessing the Reassessment of suPAR in Glomerular Disease
por: Meijers, Björn K. I., et al.
Publicado: (2015) -
suPAR to Risk-Stratify Patients With Malaria
por: Stefanova, Veselina, et al.
Publicado: (2022)